Company Overview and News
2018-08-23 business.inquirer.net - 1
The country’s largest integrated sugar producer, Roxas Holdings Inc. (RHI), has decided to sell its sugar milling and refining operations in Batangas to Gokongwei-led Universal Robina Corp. (URC).
ROX PSKXF PHSXY PSE
UNIVERSAL ROBINA Corp. (URC) on Thursday said it is acquiring the sugar milling and refining assets of Roxas Holdings, Inc.’s (RHI) subsidiary in Nasugbu, Batangas.
ROX URC UVRBY UVRBF
2018-08-10 business.inquirer.net - 1
Listed sugar and ethanol producer Roxas Holdings Inc. (RHI) saw its net income plunge by 96.5 percent for the first nine months of its fiscal year, ending in September, compared to year-ago level.
ROX PSKXF PHSXY PSE
2018-04-15 bworldonline - 2
INTEGRATED sugar and bioethanol producer Roxas Holdings, Inc. (RHI) said it is pushing for further mechanization on sugarcane farms amid fears of an aging and dwindling work force in agriculture.
2017-10-30 - Asif
The company develop and market premium and super premium brands in the following beverage alcohol categories: rum, whiskey, liqueurs, vodka and tequila. The company also develop and market related non-alcoholic beverage products, including Goslings Stormy Ginger Beer. The company distribute its products in all 50 U.S. states and the District of Columbia and in thirteen primary international markets, including Ireland, Great Britain, Northern Ireland, Germany, Canada, France, Finland, Norway, Sweden, Denmark, and the Duty Free markets. The company market the following brands, among others: Goslings rum® Goslings Stormy Ginger Beer Goslings Dark ‘n Stormy® ready-to-drink cocktail Jefferson’s® bourbon Jefferson’s Reserve® Jefferson’s Ocean Aged at Sea® Jefferson’s Wine Finish Collection Jefferson’s The Manhattan: Barrel Finished Cocktail Jefferson’s Chef’s Collaboration Jefferson’s Wood Experiment Jefferson’s Presidential Select™ Jefferson’s Straight...
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to PSE:ROX / Roxas Holdings, Inc. on message board site Silicon Investor.